Ascendis Pharma A/S

Historical 13F Holders

Symbol
ASND
CUSIP
04351P101
All holders as of
Q3 2026
Type
Equity
Class
SPONSORED ADR
Reported Value, Excluding Options
Total Shares Held, Excluding Options
Total Filers

13D/G Filers

Each filer's latest filing for 04351P101 since 12/18/2024, largest first.

Filer % of Class Filed
T. Rowe Price Investment Management, Inc. 13G/A 12.4% 11/16/2026
Event 9/30/2026
Westfield Capital Management Co LP 13G/A 8.5% 2/11/2026
Event 12/31/2025
FMR LLC 13G/A
8.0% 5/12/2025
Event 3/31/2025
Janus Henderson Group PLC 13G/A 6.0% 5/15/2026
Event 3/31/2026
Artisan Partners Limited Partnership 13G/A
5.2% 2/3/2026
Event 12/31/2025
Under 5%, checked the "5 percent or less" box, or amended by a later filing (1)
Capital International Investors 13G/A 3.2% 5/14/2026
Event 3/31/2026

13F Holders by Quarter

Period Filers Shares, Excl. Options Value, Excl. Options
2026 Q3 4 4.02 k $916k
2026 Q2 10 543 k $145M
2026 Q1 278 54.7 M $12.5B
2025 Q4 311 65.8 M $14.0B
2025 Q3 292 68.5 M $12.7B
2025 Q2 254 63.3 M $10.9B
2025 Q1 247 65.6 M $10.1B
2024 Q4 218 64.2 M $8.77B
2024 Q3 222 63.0 M $9.31B
2024 Q2 204 60.7 M $8.27B
2024 Q1 192 60.8 M $9.19B
2023 Q4 189 60.3 M $7.59B
2023 Q3 167 60.3 M $5.64B
2023 Q2 166 61.0 M $5.45B
2023 Q1 170 61.0 M $6.54B
2022 Q4 193 65.9 M $8.05B
2022 Q3 188 66.7 M $6.89B
2022 Q2 174 63.2 M $5.88B
2022 Q1 185 62.0 M $7.27B
2021 Q4 173 58.4 M $7.86B
2021 Q3 171 58.0 M $9.25B
2021 Q2 176 55.0 M $7.24B
2021 Q1 183 52.9 M $6.83B
2020 Q4 178 54.4 M $9.07B
2020 Q3 156 53.6 M $8.27B
2020 Q2 158 48.2 M $7.13B
2020 Q1 150 48.0 M $5.41B
2019 Q4 147 46.2 M $6.42B
2019 Q3 130 46.1 M $4.44B
2019 Q2 135 47.7 M $5.50B
2019 Q1 143 46.0 M $5.41B
2018 Q4 106 40.1 M $2.51B
2018 Q3 98 40.3 M $2.85B
2018 Q2 102 42.2 M $2.80B
2018 Q1 92 38.1 M $2.49B
2017 Q4 65 30.5 M $1.22B
2017 Q3 59 28.8 M $1.04B
2017 Q2 35 23.3 M $646M
2017 Q1 36 20.9 M $585M
2016 Q4 31 20.6 M $416M
2016 Q3 22 14.0 M $281M
2016 Q2 23 13.9 M $184M
2016 Q1 26 12.0 M $223M
2015 Q4 25 10.1 M $185M
2015 Q3 26 8.96 M $165M
2015 Q2 33 8.95 M $158M
2015 Q1 36 8.48 M $146M